Abstract. To determine how estrogens are involved in the growth of endometrial cancer with varying degrees of differentiation, we investigated the status of p72, a novel specific coactivator for estrogen receptor α (ERα) activation function-1 (AF-1), AIB1, a steroid receptor coactivator amplified in breast cancer 1, erbB-2, a receptor tyrosine kinase, and ERα in endometrial cancer. Gene expression of ERα, p72, AIB1 and erbB-2 was measured in 26 samples of primary endometrial cancers by real-time RT-PCR, and their in vivo cellular effects on the transactivation function of ERα were examined by a transient expression assay. The mRNA levels of erbB-2 increased and those of ERα, p72 and AIB1 decreased with the loss of histological differentiation. Transient expression of p72, AIB1 and erbB-2 in human embryonic kidney 293T cells led to a synergistic promotion of the transactivation function of ERα in the presence of 17α-estradiol or 4-hydroxytamoxifen, an ERα AF-1 agonist/AF-2 antagonist, as a ligand. In conclusion, estrogen action through ERα AF-1 might be exerted by the increased expression of the coactivators p72 and AIB1, together with cross talk between erbB-2 and p72, to accelerate the transactivation of ERα AF-1 in endometrial cancer. These findings also suggest that the cooperative transactivation of ERα AF-1 by the overexpression of p72, AIB1 and erbB-2 might be involved in tamoxifen-stimulated growth of endometrial cancer.
Introduction
Estrogen binds to estrogen receptors (ERs) which belong to the nuclear receptor superfamily and function as ligandinducible transcriptional factors to control transcription of target genes (1) (2) (3) . The N-terminal A/B domain and the C-terminal E/F domain provide transactivation functions of ER. The autonomous activation function-1 (AF-1) in the A/B domain is constitutively active while AF-2 in the E/F domain is dependent on ligand binding (4) . A ligand-bound ER forms a large complex, thought to contain basic transcriptional machinery and transcriptional cofactors, to initiate transcription (5) . CBP/p300 and SRC-1 family proteins (SRC-1/TIF2/ AIB1) are known as cofactors which bind to ERα AF-2 in a ligand-dependent manner to promote transcription (6) (7) (8) (9) . SRA is an RNA coactivator selective for ERα AF-1 (10) . In particular, AIB1 possesses a configuration that is phosphorylated by mitogen-activated protein kinase (MAPK) (11) . Recently, we found that two DEAD-box proteins, p72 and p68, form a complex with SRC-1 family proteins and SRA, functioning as specific coactivators for ERα AF-1 by directly binding to the ERα A/B domain (12) (13) (14) . The interaction of p72/68 with the ERα A/B domain was potentiated by phosphorylation of the Ser118 residue in the ERα A/B domain by MAPK, leading to the enhancement of ERα AF-1 activity (13) (14) (15) .
Endometrial cancer is the most common female genital tract malignancy in Western countries. Histologically more differentiated cases with high expression levels of sex steroid receptors respond best to hormone treatment (16) (17) (18) . EGF is known to play a regulatory role in the proliferation of endometrial cancer cells (19, 20) . Overexpression of erbB-2, a receptor tyrosine kinase similar to the EGF receptor in structure, has been reported to be associated with poor survival in patients with endometrial cancer (21, 22) . ErbB-2 initiates its intracellular signal transduction by tyrosine-phosphorylating its intracellular domain, and provides docking sites for signaling molecules (23 has been reported to be associated with cell proliferation, tumor progression and metastasis (23) . Recently, poorly-differentiated breast cancer was shown to overexpress both AIB1 and erbB-2. This was accompanied by the lack of ERs (11) . So far, however, the quantitative relationship between ERα, its transcriptional cofactors and erbB-2 in endometrial cancer has not been determined.
In the present study, we first investigated the mRNA expression levels of ERα, p72, AIB1 and erbB-2 in endometrial cancers by real-time RT-PCR. Next, in order to test whether there is cross talk between the p72 and AIB1 cofactors and erbB-2 in the transactivation of ERα, we examined their in vivo cellular effects on the transactivation function of ERα by a transient expression assay.
Materials and methods
Chemicals. An active metabolite of tamoxifen, 4-hydroxytamoxifen (OHT), and 17α-estradiol (E2) were purchased from Sigma (St. Louis, MO, USA). All other chemicals were of the highest grade commercially available. tumor extending outside uterus and including dissemination to vagina, but remaining within pelvis or metastases to regional lymph nodes); and 2 cases in stage IV (T 4 or M 1 ; tumor invading bladder or bowel mucosa or distant metastases). The histological subtype of all tumors was endometrioid adenocarcinoma (24) . The histological grading of the differentiation of these endometrioid adenocarcinomas was as follows: 10 cases, well-differentiated (G1); 10 cases, moderatelydifferentiated (G2); 6 cases, poorly-differentiated (G3) (24) . The biopsied tissue samples were snap-frozen in liquid nitrogen and stored at -70˚C.
RT and real-time PCR. Total-RNA was extracted from the frozen tissues using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA). First-stand cDNA was synthesized in a reaction volume of 20 μl containing 1 μg total-RNA using ReverTra Dash (Toyobo, Tokyo, Japan) according to the manufacturer's instructions. After the reverse transcription reaction, cDNA was amplified to determine p72, ERα, erbB-2 and AIB1 expression respectively using the following PCR primer pairs: p72, 5'-GAC CAC AAG TTG ATC CAA CTA-3' (sense) and 5'-GGC CTC TTC CAG CAC TTT GAT-3' (antisense); ERα, 5'-AGC GTG TCT CCG AGC CCG CTG-3' (sense) and 5'-GTT TTT ATC AAT GGT GCA CTG-3' (antisense); erbB-2, 5'-TTG ACT CTG AAT GTC GGC CA-3' (sense) and 5'-CCT TCG GAG GGT GCC AGT GG-3' (antisense); AIB1, 5'-ATA CTT GCT GGA TGG TGG ACT-3' (sense) and 5'-TCC TTG CTC TTT TAT TTG ACG-3' (antisense). Expression of these mRNAs was normalized to RNA loading for each sample using GAPDH mRNA as an internal standard. The primers of GAPDH were as follows: 5'-TCC ATG ACA ACT TTG GTA TCG TGG-3' (sense) and 5'-GTC GCT GTT GAA GTC AGA GGA GAC-3' (antisense).
Real-time PCR was performed with the LightCycler (Roche Applied Science, Mannheim, Germany) in 20 μl consisting of 1.6 mM MgCl 2 , 2 μl LightCycler-FastStart Reaction Mix SYBR-Green 1 (Roche Applied Science), 0.25 μM of each primer and 50 ng cDNA from RT reactions as a template. After an initial denaturation at 95˚C for 10 min, the amplification program for p72, ERα, erbB-2, AIB1 and GAPDH consisted of 35 cycles of denaturation for 15 sec at 95˚C, annealing for 8 sec at 64˚C and extension for 11 sec at 72˚C. Finally, the temperature was raised gradually (0.2˚C/sec) from the annealing temperature to 95˚C for the melting curve analysis.
The samples were analyzed according to the following procedure. Concentrations of the samples were extrapolated from the standard curve by LightCycler software. Exogenous cDNA standards for p72, ERα, erbB-2, AIB1 and GAPDH were produced by inserting PCR products, generated using the sample primers noted above, and endometrial cancer tissue specimen cDNA templates into the pCR2.1 vector with the TOPO TA Cloning Kit (Invitrogen Corp., Carlsbad, CA, USA). The concentration of each standard was determined by measuring the OD260, and the copy number was calculated. Relative expression levels of p72, ERα, erbB-2 and AIB1 were calculated by subtracting the signal threshold cycle (C T ) of the internal standard (GAPDH) from the C T of p72, ERα, erbB-2 and AIB1.
Luciferase assay. Human embryonic kidney 293T cells were transfected using Lipofectin reagent (Invitrogen Corp.). A luciferase reporter plasmid containing CMV promoter (pRL-CMV) and estrogen response element with thymidine kinase promoter (pGL-ERE-tk) was co-transfected with the expression vectors indicated in the legend of Fig. 2 . A luciferase reporter assay was performed using the DualLuciferase Reporter Assay System (Promega, Madison, WI, USA), as described previously (13) .
Statistical analysis. Data represent the mean ± SEM. The statistical analysis of relative mRNA expression levels of ERα, p72, AIB1 and erbB-2 was performed by the Mann-Whitney U test. A P-value <0.05 was considered statistically significant.
Results

mRNA expression levels of erbB-2, p72, AIB1 and ERα in endometrial cancers.
Real-time quantitative RT-PCR revealed that mRNA levels of erbB-2 (G1, 1.00±0.09; G2, 2.67±0.39; G3, 7.12±1.32) were higher in poorly-differentiated endometrial cancers than in well-differentiated cases, whereas mRNA levels of ERα (G1, 1.00±0.42; G2, 0.76±0.25; G3, 0.24±0.12), p72 (G1, 1.00±0.20; G2, 0.70±0.13; G3, 0.16±0.08) and AIB1 (G1, 1.00±0.32; G2, 0.80±0.18; G3, 0.36±0.09) decreased with the loss of histological differentiation (Fig. 1) . No relationship was found between these mRNA levels and clinical stage.
Synergistic action of erbB-2 with p72 and AIB1 in the transactivation function of ERα.
Luciferase assay revealed that the transient expression of erbB-2 promoted the transactivation function of ERα synergistically with p72 and AIB1 in the presence of E2 as a ligand (Fig. 2) . A similar result was obtained with OHT, although the transcriptional activity of ERα with E2 was greater than it was with OHT.
Discussion
In the present study, we demonstrated that p72, a specific coactivator for ERα AF-1, as well as AIB1 and ERα mRNA levels decreased with a loss of histological differentiation, whereas those of erbB-2 increased inversely. These findings lead us to postulate that, in poorly-differentiated endometrial cancer tissues, estrogen-independent ERα AF-1 activity appears to be maintained by a compensatory increase in the expression of erbB-2, despite a smaller quantity of p72, AIB1 and ERα. It is also likely that the potentiation of the transactivation of ERα AF-1 by erbB-2-activated MAPK phosphorylation of p72, AIB1 and ERα may in itself lead to the estrogenindependent transactivation of target genes (11, (13) (14) (15) .
We additionally showed that the transient expression of p72, AIB1 and erbB-2 synergistically promoted the transactivation function of ERα in the presence of E2 or OHT as a ligand. It is known that tamoxifen functions as an agonist to ERα AF-1 and as an antagonist to AF-2 (13, 25) . In our study, the transcriptional activity of ERα with E2 was greater than it was with OHT. The reason may be that E2-bound ERα is transactivated through both AF-1 and AF-2, whereas OHTbound ERα is transactivated through AF-1 alone. Tamoxifen is thought to improve disease-free survival in women with breast cancer, whereas it increases the risk of endometrial cancer, especially in estrogen-deficient post-menopausal women (26, 27) . In light of the paradoxical growth effects of tamoxifen in endometrial tissues as opposed to the breasts, it is likely that ERα AF-1 activity varies in different tissues. Thus, it seems that ERα AF-1 activity might be enhanced as a result of an ERα AF-1-specific coactivator such as p72 being overexpressed in endometrial tissues where tamoxifen functions as an estrogen agonist. The existence of tissue-specific cofactors could explain the difference in tissue-specific ligand action.
These results suggest that estrogen action through ERα AF-1 might be activated by the increased expression of p72 and its cross talk with erbB-2 in well-differentiated endometrial cancer, and that in poorly-differentiated endometrial cancer there might be a compensatory increase in the expression of erbB-2 to maintain ERα AF-1 activity. In addition, the cooperative transactivation of ERα AF-1 by the overexpression of p72, AIB1 and erbB-2 might explain the mechanisms underlying the growth of tamoxifen-induced endometrial cancer. Given the positive relationship between degree of differentiation and the expression level of p72, this study further highlights p72 as a potential prognostic marker in various estrogen-related diseases.
